ClinicalTrials.gg
CompletedNCT02750410Updated Sep 24, 2019Results posted

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

A Phase 4 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
27th of 54
159 · median 159
Started
2016
with 2 others
Phase 4
9 of 54
2 open now
Registered
31st of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 3 that started in 2016, is one of 9 in phase 4, and was the 31st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of combination therapy with dulaglutide and insulin in Japanese participants with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have had a diagnosis of type 2 diabetes mellitus
  • Participants who have been treated with insulin therapy (basal insulin, premixed insulin, or basal/mealtime insulin regimen) with or without 1 or 2 oral antidiabetics (OADs) at stable dose for at least 3 months before screening
  • Participants who have an value ≥7.0% and ≤10.5% at screening if the participant is washing out OADs (dipeptidyl peptidase-4 [DPP-4] inhibitors, sulfonylurea [SU], or glinides) or ≥7.5% and ≤10.5% at screening if the participant is not washing out OADs
  • Participants who have stable weight (±5%) ≥3 months prior to screening
  • Participants who have a (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Participants who have a diagnosis of type 1 diabetes
  • Participants who have previously received therapy with a glucagon-like peptide-1 receptor agonist within 3 months prior to screening
  • Participants who have been previously treated with dulaglutide prior to screening
  • Participants who have been treated with 2 of the following at screening: DPP-4 inhibitor, SU, and glinide (ie, DPP-4 inhibitor and SU, or DPP-4 inhibitor and glinide)
  • Participants who have been treated with continuous subcutaneous insulin infusion (CSII) at screening
  • Participants who have gastric emptying abnormality, hepatitis, pancreatitis, renal dysfunction, or thyroid abnormalities
  • Participants who have a history of clinically significant cardiovascular disease, transplanted organ, or active or untreated
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Dulaglutide

    Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.

    Drug: Dulaglutide

  • Placebo comparator
    Placebo

    Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.

    Drug: Dulaglutide · Drug: Placebo

Interventions

  • Administered subcutaneously (SC)

    Also known as: LY2189265

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline HbA1c, treatment, visit, and treatment-by-visit insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percentage of Participants With HbA1c <7.0% or ≤6.5%

    Percentage of participants whose HbA1c was \<7.0% or ≤6.5%. HbA1c \<7.0% is presented.

    Time frame: Week 16

  2. Change From Baseline in Fasting Serum Glucose (FSG)

    The LS mean change from baseline in FSG was calculated using a REML based MMRM and adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c Group (\<8.5%, \>=8.5%) + insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.

    Time frame: Baseline, Week 16

  3. Change From Baseline in Plasma Glucose From 7-Point Self-Monitored Blood Glucose Profiles (SMBG)

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: prebreakfast blood glucose (BG), breakfast 2-hour postprandial blood glucose (PPBG), prelunch BG, lunch 2-hour PPBG, predinner BG, dinner 2-hour PPBG, and bedtime BG. LS mean was calculated with fixed effect test of analysis of covariance (ANCOVA) model and adjusted by, baseline value, treatment, baseline HbA1c Group (\<8.5%, ≥8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin).

    Time frame: Baseline, Week 16

  4. Change From Baseline in Body Weight

    LS mean change from baseline in body weight was calculated using a REML based MMRM and was adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c group (\<8.5%, \>=8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Daily Total Insulin Dose

    Mean change from baseline in total insulin dose was measured in each treatment groups.

    Time frame: Baseline, Week 16

07

Results

Posted Sep 16, 2019

Participant flow

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestonePlaceboDulaglutide
Started39120
Received at least one dose of study drug39120
Completed37117
Not completed23
Withdrew: Adverse event22
Withdrew: Withdrawal by subject01
Open-Label Extension Period
Participant flow — Open-Label Extension Period
MilestonePlaceboDulaglutide
Started37117
Completed31111
Not completed66
Withdrew: Adverse event53
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline HbA1c, treatment, visit, and treatment-by-visit insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cPlaceboDulaglutide
Change From Baseline in Hemoglobin A1c (HbA1c)0.06 ± 0.099-1.45 ± 0.057
Statistical analysis
  • Placebo · Mixed Models Analysis · p = <0.001 · Ls mean percent difference: -1.50 · 95% CI -1.73 to -1.28
SecondaryPercentage of Participants With HbA1c <7.0% or ≤6.5%

Percentage of participants whose HbA1c was \<7.0% or ≤6.5%. HbA1c \<7.0% is presented.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.0% or ≤6.5%
percentage of participantsPlaceboDulaglutide
Percentage of Participants With HbA1c <7.0% or ≤6.5%47.40
Statistical analysis
  • Placebo vs Dulaglutide · Regression, Logistic · p = 0.003 · Odds ratio (or): 0.117 · 95% CI 0.028 to 0.479
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

The LS mean change from baseline in FSG was calculated using a REML based MMRM and adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c Group (\<8.5%, \>=8.5%) + insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · milligram/deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram/deciliter (mg/dL)PlaceboDulaglutide
Change From Baseline in Fasting Serum Glucose (FSG)-4.1 ± 4.94-34.2 ± 2.78
Statistical analysis
  • Placebo vs Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -30.14 · 95% CI -41.37 to -18.91
SecondaryChange From Baseline in Plasma Glucose From 7-Point Self-Monitored Blood Glucose Profiles (SMBG)

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: prebreakfast blood glucose (BG), breakfast 2-hour postprandial blood glucose (PPBG), prelunch BG, lunch 2-hour PPBG, predinner BG, dinner 2-hour PPBG, and bedtime BG. LS mean was calculated with fixed effect test of analysis of covariance (ANCOVA) model and adjusted by, baseline value, treatment, baseline HbA1c Group (\<8.5%, ≥8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin).

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline in Plasma Glucose From 7-Point Self-Monitored Blood Glucose Profiles (SMBG)
mg/dLPlaceboDulaglutide
Prebreakfast BG12.30 ± 4.37-14.28 ± 2.52
Breakfast 2-hour PPBG13.15 ± 7.35-32.24 ± 4.19
Prelunch BG8.08 ± 5.56-28.74 ± 3.18
Lunch 2-hour PPBG10.74 ± 7.39-39.42 ± 4.54
Predinner BG5.66 ± 5.74-25.61 ± 3.28
Dinner 2-hour PPBG3.97 ± 7.91-30.99 ± 4.48
Bedtime BG13.21 ± 7.78-28.24 ± 4.45
Statistical analysis
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -26.59 · 95% CI -36.39 to -16.78
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -45.38 · 95% CI -61.77 to -29.00
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -36.82 · 95% CI -49.20 to -24.45
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -50.16 · 95% CI -67.85 to -32.46
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -31.27 · 95% CI -44.05 to -18.48
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -34.97 · 95% CI -52.55 to -17.38
  • Placebo vs Dulaglutide · t-test, 2 sided · p = <0.001 · Ls mean difference: -41.45 · 95% CI -58.81 to -24.09
SecondaryChange From Baseline in Body Weight

LS mean change from baseline in body weight was calculated using a REML based MMRM and was adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c group (\<8.5%, \>=8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)PlaceboDulaglutide
Change From Baseline in Body Weight-0.30 ± 0.302-0.20 ± 0.171
Statistical analysis
  • Placebo vs Dulaglutide · Mixed Models Analysis · p = 0.776 · Ls mean difference: 0.10 · 95% CI -0.59 to 0.78
SecondaryChange From Baseline in Daily Total Insulin Dose

Mean change from baseline in total insulin dose was measured in each treatment groups.

Time frame:
Baseline, Week 16
Reported as:
Mean · International Units (IU)/Day
Change From Baseline in Daily Total Insulin Dose
International Units (IU)/DayPlaceboDulaglutide
Change From Baseline in Daily Total Insulin Dose-0.3 ± 1.2-1.1 ± 3.1

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Double-Blind (DB) Treatment Period0/39 (0%)0/39 (0%)18/39 (46.2%)
Dulaglutide 0.75 mg DB Treatment Period0/120 (0%)3/120 (2.5%)47/120 (39.2%)
Placebo DB Treatment, Dulaglutide 0.75 mg Extension Period0/39 (0%)1/39 (2.6%)28/39 (71.8%)
Dulaglutide 0.75 mg DB Treatment/Extension Period0/120 (0%)6/120 (5%)59/120 (49.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo Double-Blind (DB) Treatment PeriodDulaglutide 0.75 mg DB Treatment PeriodPlacebo DB Treatment, Dulaglutide 0.75 mg Extension PeriodDulaglutide 0.75 mg DB Treatment/Extension Period
DepressionPsychiatric disorders0/390/1201/390/120
Suicide attemptPsychiatric disorders0/390/1201/390/120
CataractEye disorders0/390/1200/391/120
Large intestine polypGastrointestinal disorders0/390/1200/391/120
HypoglycaemiaMetabolism and nutrition disorders0/391/1200/391/120
MyositisMusculoskeletal and connective tissue disorders0/391/1200/391/120
OsteoarthritisMusculoskeletal and connective tissue disorders0/391/1200/391/120
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/390/1200/391/120
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlacebo Double-Blind (DB) Treatment PeriodDulaglutide 0.75 mg DB Treatment PeriodPlacebo DB Treatment, Dulaglutide 0.75 mg Extension PeriodDulaglutide 0.75 mg DB Treatment/Extension Period
NasopharyngitisInfections and infestations7/3919/12012/3934/120
Abdominal discomfortGastrointestinal disorders1/3910/1205/3911/120
ConstipationGastrointestinal disorders4/398/1205/3913/120
DiarrhoeaGastrointestinal disorders0/395/1203/3910/120
DyspepsiaGastrointestinal disorders1/392/1203/392/120
VomitingGastrointestinal disorders2/393/1203/396/120
InfluenzaInfections and infestations0/392/1203/395/120
Decreased appetiteMetabolism and nutrition disorders0/398/1202/399/120
NauseaGastrointestinal disorders2/397/1202/397/120
PalpitationsCardiac disorders1/391/1202/392/120

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboDulaglutideTotal
Mean59.1 ± 10.6859.3 ± 10.2359.3 ± 10.31
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDulaglutideTotal
Female194261
Male207898
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDulaglutideTotal
Hispanic or Latino000
Not Hispanic or Latino39120159
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDulaglutideTotal
American Indian or Alaska Native000
Asian39120159
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboDulaglutideTotal
Japan39120159
Percentage of Hemoglobin A1c (HbA1c) at Baseline
Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)PlaceboDulaglutideTotal
Mean8.64 ± 0.728.50 ± 0.698.53 ± 0.70
Percentage of Participants with Insulin regimen
Percentage of Participants with Insulin regimen(percentage of insulin regimen)PlaceboDulaglutideTotal
Basal43.643.343.4
Premixed23.121.722.0
Basal/meal time33.335.034.6
08

Study locations

25 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adachi-ku, 123-0845, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 2610004, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiyoda, 102-0082, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chuo-ku, 103-0027, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Chuo-ku, 103-0028, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chuou-ku, 1030002, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fuchu, 183-8524, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ichikawa, 272-8516, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Isahaya, 8548501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kamakura, 247-0056, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kashihara, 634-8522, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 862-0965, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kumamoto, 862-0976, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Maebashi-City, 3710821, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Mito, 310-0845, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Naka, 311-0113, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Nishinomiya, 662-0971, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Ooita, 870-0039, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Osaka, 530-0001, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Sasebo, 857-1195, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Shimotsuke, 329-0433, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shizuoka, 424-0855, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Tama, 206-0633, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toda, 335-0023, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yokohama, 241-0821, Japan
09

References and documents

Publications

  • Onishi Y, Ishii H, Oura T, Takeuchi M. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen. Diabetes Ther. 2020 Mar;11(3):735-745. doi: 10.1007/s13300-020-00765-6. Epub 2020 Jan 29. PubMed 31994009 ↗
  • Ishii H, Onishi Y, Oura T, Takeuchi M. Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study. Diabetes Ther. 2020 Jan;11(1):133-145. doi: 10.1007/s13300-019-00726-8. Epub 2019 Nov 22. PubMed 31758520 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2016
First posted
Apr 25, 2016
Start
Aug 2016
Primary completionActual
Jun 18, 2018
CompletionActual
Jun 18, 2018
Results first posted
Sep 16, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02750410
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
Aug 2016
Primary completion
Jun 18, 2018
Completion
Jun 18, 2018
Results posted
Sep 16, 2019
Last update
Sep 24, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion